Revenue primarily driven by RoW market: Sales were up 16% YoY to INR82.5b in 1QFY20, mainly led by strong growth in RoW sales (+56% YoY to USD167m partly led by the integration of the recently acquired Pola Pharma Japan since Jan'19). US sales increased 12% YoY to USD424m (36% of total sales), mainly driven by a significant contribution from generic supply to a customer. India sales were up 8% YoY to INR23b, while emerging market sales were flat YoY at USD194m. Taro sales were up 4% YoY at USD161m. India distribution transition impacts gross margin: Gross margin shrank...